HC Wainwright & Co. analyst Robert Burns reiterates Exelixis (NASDAQ:EXEL) with a Buy and mai

Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin

Truist Securities analyst Gregory Renza downgrades Exelixis (NASDAQ:EXEL) from Buy to Hold and ra

Citizens analyst Silvan Turkcan maintains Exelixis (NASDAQ:EXEL) with a Market Outperform and rai

Exelixis reported final STELLAR-303 data showing a survival trend for zanzalintinib combo in metasta

Exelixis, Inc. (NASDAQ:EXEL) today announced results from the final analysis of the dual primary end

STELLAR-316 is a planned phase 3 pivotal trial in patients with resected stage II/III colorectal can

Top Wall Street analysts changed their outlook on top names. See all rating changes, including upgra

HC Wainwright & Co. analyst Robert Burns maintains Exelixis (NASDAQ:EXEL) with a Buy and rais

TD Cowen analyst Yaron Werber maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price ta

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raise

Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price t

Wells Fargo analyst Eva Fortea Verdejo maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and r

Dr. Morrissey continued: "Our R&D organization is on track to deliver multiple milestones th

Exelixis (NASDAQ:EXEL) affirms FY2026 sales outlook from $2.525 billion-$2.625 billion to $2.525 bil

Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.87 per share which beat the analyst consens

Merck stock falls as the Phase 3 LITESPARK-012 trial for advanced renal cell carcinoma fails to meet

RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and lo

Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidanc

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record

Wall Street could go from strength to strength as the index futures point to another session in the

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1

Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is estimated to report earnings for it

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

Companies Reporting Before The Bell • BP (NYSE:BP) is likely to report quarterly earnings at $1.67

Upgrades

Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.

  On Tuesday, 838 companies hit new 52-week lows.